工程双重VHHs针对不同的表位,以增强抗体依赖细胞介导的细胞毒性
Yuqiang Xu1, Hao Jiang1, Limin Chen1
1Research & Development Department, Tavotek Biotherapeutics, Suzhou, China.
FEBS open bio
|November 20, 2025
概括
使用VHH臂的双特异性抗体 (BsAbs) 的工程增强了抗体依赖细胞介导的细胞毒性 (ADCC) 以消除癌细胞. 一个对抗EGFR纳米体的合格式通过交叉链接EGFR分子显示出优异的ADCC活性.
科学领域:
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
- 在瘤学瘤学.
背景情况:
- 抗体依赖细胞中介细胞毒性 (ADCC) 是消除细胞的一种机制.
- 双特异性抗体 (BsAbs) 可以被设计成增强治疗疗效.
研究的目的:
- 在双特异抗体 (BsAb) 格式上设计单域VHH臂,以调节细胞结合和ADCC活性.
- 调查不同BsAb格式 (单价,双价,合) 对抗表皮生长因子受体 (EGFR) 表达的癌细胞的ADCC活性的影响.
主要方法:
- 使用两个抗EGFR纳米体 (7D12和EGA1) 构建BsAbs,以单价,双价和联格式,与人类IgG1 Fc域融合.
- 在各种癌症细胞系中评估细胞结合和ADCC活性.
主要成果:
- 与单个纳米体或其他格式相比,双重7D12-EGA1 BsAb格式显示出明显更强的ADCC活性.
- 这种增强的ADCC活性在没有显著改变细胞结合亲和力的情况下实现.
- 能够使两个不同的EGFR分子交叉链接的分子设计被确定为改善ADCC的关键因素.
结论:
- 工程BsAbs与VHH手臂在一个协同格式可以显著提高ADCC活动.
- 双重7D12-EGA1 BsAb显示了通过通过EGFR交叉链接增强ADCC改善癌细胞消除的潜力.
关键词:
ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC is also known as ADCC ADCC ADCC is also known as ADCC欧洲农业基金会 (EGFR) 是一个基金.工程 VHHHH 的工程.两种特异性抗体的抗体单个域抗体的抗体.更多相关视频
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
10.1K
08:10Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector
Published on: November 28, 2018
9.0K
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Hybridoma Technology
17.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.2K
Cytotoxic T Cells-mediated Immune Response
6.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.4K
